HEALTH
Drug for diabetes and kidney disease may also lower heart attack, stroke risks – Medical News Today
- Drug for diabetes and kidney disease may also lower heart attack, stroke risks Medical News Today
- Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) Yahoo Finance
- ‘First of its kind’ medication can significantly reduce heart attacks and strokes New York Post
- A diabetes, heart failure, and kidney disease EurekAlert
- Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD MD Magazine
Source link
